肾衰竭患者起始GLP-1受体激动剂的心血管结局比较
本研究基于美国肾脏数据系统(2011-2021)电子健康记录与医保数据,在维持性透析的2型糖尿病患者中比较新起始GLP-1受体激动剂(GLP-1 RA)与DPP-4抑制剂或磺脲类的心血管结局。倾向评分匹配后,GLP-1 RA较DPP-4抑制剂降低主要不良心血管事件(MACE)、全因死亡和心衰住院风险,较磺脲类降低MACE和全因死亡风险。
要点
- 透析的2型糖尿病患者起始GLP-1 RA较DPP-4抑制剂降低MACE风险13%。
- GLP-1 RA较DPP-4抑制剂降低全因死亡风险17%和心衰住院风险10%。
- GLP-1 RA较磺脲类降低MACE风险17%和全因死亡风险20%。
核心结论
- 在维持性透析的2型糖尿病患者中,起始GLP-1 RA与其他常用降糖药相比与较低的心血管事件和全因死亡风险相关。
研究设计与样本
- 基于美国肾脏数据系统(2011-2021)电子健康记录、Medicare索赔和Part D数据的回顾性队列研究。
- 新用户包括GLP-1 RA(n=3629)、DPP-4抑制剂(n=21369)和磺脲类(n=32296)。
- 主要分析为GLP-1 RA与DPP-4抑制剂1:1倾向评分匹配(61个协变量),预设次要分析为GLP-1 RA与磺脲类匹配。
主要发现
- GLP-1 RA vs DPP-4抑制剂(3284对匹配):MACE风险HR 0.87(95%CI 0.78-0.97),全因死亡HR 0.83(95%CI 0.74-0.94),心衰住院HR 0.90(95%CI 0.83-0.99),随访至多2年。
- GLP-1 RA vs 磺脲类(2792对匹配):MACE风险HR 0.83(95%CI 0.74-0.93),全因死亡HR 0.80(95%CI 0.69-0.91)。
关键数值与推荐
- 主要结局为改良MACE复合终点(心肌梗死、卒中或全因死亡)。
- 次要结局包括主要结局各组分和心衰住院。
- 使用病因特异性Cox模型估计风险比(HR)。
临床怎么用
- 对于维持性透析的2型糖尿病患者,起始GLP-1 RA可能与较DPP-4抑制剂或磺脲类更低的心血管事件和死亡风险相关。
- 临床决策时可结合患者个体情况考虑GLP-1 RA作为降糖方案选择之一。
局限性
- 原文未明确报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Glucagon-like peptide-1 receptor agonists are increasingly used in patients with kidney failure despite trial exclusion. Initiation was associated with a 13% lower risk of cardiovascular events and 17% lower mortality versus dipeptidyl peptidase-4 inhibitors. Initiation was associated with a 10% lower risk of heart failure hospitalization versus dipeptidyl peptidase-4 inhibitors. BACKGROUND: Few therapies improve cardiovascular outcomes for people with kidney failure. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) reduce cardiovascular risk in patients with non-dialysis-dependent CKD, but the cardiovascular benefits in patients with kidney failure remain uncertain. The objective of this study was to compare cardiovascular outcomes among patients with kidney failure and type 2 diabetes newly initiated on GLP-1 RA versus other antiglycemic agents. METHODS: We analyzed electronic health records, Medicare claims, and Part D data from the United States Renal Data System (2011-2021) to identify new users of GLP-1 RA ( n =3629), dipeptidyl peptidase-4 inhibitors (DPP4i; n =21,369), and sulfonylureas ( n =32,296) among patients with type 2 diabetes receiving maintenance dialysis. For the primary analysis, we performed 1:1 propensity score matching of GLP-1 RA to DPP4i initiators using 61 covariates. A prespecified secondary analysis compared propensity score-matched initiators of GLP-1 RA and sulfonylureas. The primary outcome was a modified major adverse cardiovascular event (MACE) composite of myocardial infarction, stroke, or all-cause mortality. Secondary outcomes included the individual components of the primary outcome and hospitalizations for heart failure. Cause-specific Cox models were used to estimate hazard ratios (HRs). RESULTS: Among 3284 matched pairs of GLP-1 RA and DPP4i initiators, GLP-1 RA use was associated with lower risks of MACE (HR, 0.87; 95% confidence interval [CI], 0.78 to 0.97), all-cause mortality (HR, 0.83; 95% CI, 0.74 to 0.94), and heart failure hospitalization (HR, 0.90; 95% CI, 0.83 to 0.99) over up to 2 years of follow-up. Among 2792 matched pairs, GLP-1 RA and sulfonylurea initiators, GLP-1 RA was associated with lower risks of MACE (HR, 0.83; 95% CI, 0.74 to 0.93) and all-cause mortality (HR, 0.80; 95% CI, 0.69 to 0.91). CONCLUSIONS: Among patients with type 2 diabetes receiving maintenance dialysis, GLP-1 RA initiation was associated with lower risk of cardiovascular events and all-cause mortality compared with other commonly prescribed antiglycemic agents. PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2026_06_12_ASN0000001061.mp3.
引用
- Catanese B, Miller C, Wolf M, et al. Cardiovascular Outcomes among New Users of GLP-1 Receptor Agonists Compared with DPP-4 Inhibitors and Sulfonylureas in Kidney Failure. J Am Soc Nephrol. 2026. PMID: 41817629. doi:10.1681/ASN.0000001061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。